Growth Ahead In Market For Vein-Viewing Technologies
Executive Summary
Patient safety concerns and limited payments for hospital-acquired conditions (HACs) are fueling double-digit growth in the multibillion-dollar market for point-of-care vascular imaging devices as hospitals increasingly look to these vein-viewing technologies to improve patient satisfaction and minimize complications associated with venous access procedures.
You may also be interested in...
New Products In Brief
Recent product approvals and launches
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.